Dr. Saurabh Saha, MD, PhD, is Chief Executive Officer and a member of the Board of Directors of Centessa Pharmaceuticals. Most recently, as Senior Vice President of Research & Development at Bristol Myers Squibb Company, Saurabh led translational medicine across all therapeutic areas spanning discovery, early development through late development, and commercialization. In 2019, he led the Research & Development diligence in the acquisition of Celgene by BMS and subsequently managed key aspects of the integration across both organizations. During his tenure, Saurabh laid the foundation for the BMS Research & Development headquarters in Cambridge, Massachusetts, USA serving as site head and establishing a research focus on discovering new cancer treatments for immunotherapy resistance.
Previously, Saurabh was a Venture Partner at Atlas Venture where he held leadership positions with several portfolio biotech companies, including Chief Medical Officer of Synlogic, and Chief Executive Officer of Delinia until its sale to Celgene in early 2017.
In 2008, he established the translational research and development organization at BioMed Valley Discoveries where he served as Chief Scientific Officer and later President and was responsible for leading the development and demonstrating human effectiveness of two first-in-class cancer therapies.
Earlier in his career, Saurabh was a Management Consultant in the pharmaceutical practice at McKinsey & Company and subsequently appointed Director and Head of the New Indications Discovery Unit at Novartis. He is on the editorial boards of several medical journals and is an Associate Member and Global Clinical scholar at Harvard Medical School.
Saurabh holds an MD and PhD in cancer genetics from The Johns Hopkins School of Medicine, where he completed his graduate studies in Bert Vogelstein’s lab. He is an alumnus of Harvard Business School and Oxford University, studying General Management and Biophysics respectively. Saurabh received a BSc in Biochemistry from the California Institute of Technology (Caltech).
What is Saurabh Saha's net worth?
The estimated net worth of Saurabh Saha is at least $345,800.00 as of June 24th, 2022. Dr. Saha owns 38,000 shares of Centessa Pharmaceuticals stock worth more than $345,800 as of April 25th. This net worth estimate does not reflect any other investments that Dr. Saha may own. Additionally, Dr. Saha receives a salary of $957,670.00 as CEO at Centessa Pharmaceuticals. Learn More about Saurabh Saha's net worth.
What is Saurabh Saha's salary?
How do I contact Saurabh Saha?
The corporate mailing address for Dr. Saha and other Centessa Pharmaceuticals executives is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. Centessa Pharmaceuticals can also be reached via phone at 44-73-9178-9784 and via email at [email protected]. Learn More on Saurabh Saha's contact information.
Has Saurabh Saha been buying or selling shares of Centessa Pharmaceuticals?
Saurabh Saha has not been actively trading shares of Centessa Pharmaceuticals during the last quarter. Most recently, on Friday, June 24th, Saurabh Saha bought 10,000 shares of Centessa Pharmaceuticals stock. The stock was acquired at an average cost of $4.63 per share, with a total value of $46,300.00. Following the completion of the transaction, the chief executive officer now directly owns 38,000 shares of the company's stock, valued at $175,940. Learn More on Saurabh Saha's trading history.
Who are Centessa Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Centessa Pharmaceuticals?
In the last year, insiders at the sold shares 6 times. They sold a total of 114,211 shares worth more than $972,938.86. The most recent insider tranaction occured on March, 25th when insider Karen M Anderson sold 51,160 shares worth more than $607,780.80. Insiders at Centessa Pharmaceuticals own 11.5% of the company.
Learn More about insider trades at Centessa Pharmaceuticals. Information on this page was last updated on 3/25/2024.
